Research digest · GHRH(1-29) secretagogue
Sermorelin is a GHRH(1-29) growth-hormone secretagogue studied in aging and the GH/IGF-1 axis.
A friendly, plain-English digest of what the sermorelin studies actually found — how it nudges the body to make its own growth hormone, what older-men trials measured, and where the honest evidence gaps are. Every number is cited.
The short version
Sermorelin is a small lab-made peptide — a short chain of amino acids (the building blocks of proteins). It copies the first 29 pieces of a natural brain hormone called GHRH (growth hormone-releasing hormone), the signal your body uses to tell the pituitary gland (a pea-sized gland under the brain) to release growth hormone. So sermorelin doesn't give you growth hormone directly. It taps the gland on the shoulder and asks it to make more of your own [2][3].
Why do people care? Your natural GHRH signal fades as you age, and growth hormone drops with it. In a 14-day study, older men given sermorelin's parent peptide saw their growth hormone and IGF-1 (the downstream hormone that does much of GH's work) climb back toward the levels of young men [2]. That's the headline that drives most interest.
What to watch for: sermorelin is not an approved anti-aging drug, the long-term adult data are thin, and a major medical journal called this kind of use "not yet ready for prime time" [5]. What people report — including the downsides — is on the effects page.
What is sermorelin
Sermorelin is the amidated 1-29 fragment of human GHRH — the shortest piece of that hormone that still does the full job at the GHRH receptor [6]. In plain terms: scientists found that you don't need the whole 44-amino-acid hormone to get the signal across; the first 29 amino acids carry the full message, and that's what sermorelin is.
It belongs to a family called secretagogues — substances that prompt a gland to secrete something. Here the something is growth hormone (GH), and the gland is the pituitary. Sermorelin lands on the GHRH receptor on the pituitary's growth-hormone cells (called somatotrophs) and switches on an internal relay — the cAMP/PKA pathway — that tells the cell to release GH [6].
The key difference from injecting growth hormone itself: because sermorelin works one step upstream, your body's own brakes still work. A hormone called somatostatin and the feedback from IGF-1 keep the response inside the natural range and preserve the natural pulse-by-pulse rhythm of GH release [4]. That "keep the body in charge" design is the central argument made for it in the aging literature [4].
Sermorelin peptide: what the older-men studies measured
The reason a sermorelin peptide digest leads with aging is that the most-cited human work was done in older adults. In healthy older men (mean age 68), the parent peptide GHRH(1-29) given under the skin at 0.5 mg and 1 mg twice daily for 14 days produced dose-related rises in 24-hour growth hormone and IGF-1 [2]. After the higher dose, the men's GH and IGF-1 measures no longer differed from those of young men — and fasting blood sugar didn't change [2].
That is a striking, specific result: a short course of a GHRH peptide moved an age-related decline back toward a younger pattern, at least on the lab numbers, over two weeks. It is not the same as proving long-term benefit, and the study didn't test that. But it's the anchor finding, and it's why so much of the sermorelin research revolves around the aging GH/IGF-1 axis.
The pediatric side of the record is older and more established. In growth-hormone-deficient children, once-daily sermorelin under the skin sped up growth — first-year height velocity rose from about 4.1 cm/year to roughly 7-8 cm/year — without pushing IGF-1 too high [1]. That children's-growth use is the one sermorelin was actually approved for; see the about page for the regulatory history.
How it actually works, in everyday terms
Picture the growth-hormone system as a thermostat. The brain sends a "make more" signal (GHRH) and a "that's enough" signal (somatostatin). Sermorelin boosts the "make more" side, but it leaves the "that's enough" side fully intact [4].
When sermorelin binds the GHRH receptor, it raises a messenger inside the cell called cAMP, which switches on an enzyme called PKA, which tells the somatotroph cell to release a pulse of growth hormone [6]. The growth hormone then travels to the liver, where it drives production of IGF-1 — the hormone that carries out much of GH's effect on tissue [6]. IGF-1 also feeds back to dial the system down, so it can't run away [11].
Growth hormone is released in pulses, especially during deep sleep, not as a steady drip. Because sermorelin works through the body's own pulse machinery rather than replacing the hormone, it tends to preserve that natural rhythm [4]. A 2025 authoritative review lays out this GHRH-receptor signaling and the wider GH/IGF-1 axis in full [6].
What people use it for — and where to read more
In the research literature, sermorelin and its close relatives have been studied for the aging GH/IGF-1 axis [2], children's growth [1], body composition and cognition (mostly via the related analog tesamorelin) [7], and as a more physiologic alternative to recombinant growth hormone in adults with low GH [4].
For a plain-language tour of the reported effects, the studied doses, and the safety picture, three pages do the work: sermorelin benefits summarizes the upside the studies report; sermorelin before and after walks through the measured changes; and the sermorelin effects page covers what people report alongside the cited cautions.
One honest note up front, because it matters: a 2008 editorial in a leading internal-medicine journal concluded that using growth-hormone secretagogues to fight aging is "not yet ready for prime time" [5]. This site treats that caution as a feature, not a footnote — every claim here is tied to a study you can check in the sermorelin references.